We are trying to achieve both. And right now, greater than 40% of our target list has already written. And remember, our target list is a very substantial target list with a very small sales force. But also of those 40% that have already written, 60% of those writers have found more than two patients already to write. And so that’s really encouraged from both a depth and a breadth standpoint, and we think that expanding the sales force will further accelerate the launch uptake. In terms of composition and pull of candidates, our first recruit, I think we had greater than 90% with CNS experience, more than that with psych experience. We are obviously going to – that is our goal for this expansion piece as well.
Raghuram Selvaraju: Thank you.
Operator: Thank you. Next question today is coming from Joon Lee from Truist Securities. Your line is now live.
Joon Lee: Hi. Congrats on the strong quarter. And thanks for taking our questions. Any particular reason why the SYMPHONY trial in narcolepsy got pushed out to fourth quarter? And if by trial completion, you’re also referring to completion and data readout or just a trial completion stuff. And also similar to Alzheimer’s agitation if by completion of trial in the first half of next year, we can also expect data in the first half of next year? Thank you. And I have a quick follow-up.
Nick Pizzie: Thanks for the questions. So with regards to SYMPHONY, we’re on track to complete the study and report results out in the fourth quarter. And this is not a change from our last update. And the reason for the – for granularity around the timing of the AXS-12 trial is that this is an orphan medication and orphan indications they – could not be. So let me try and provide granularity as we get closer. And so, we’re on track there. With regards to – yes, I think the nuance is that it’s – the prior guidance of completion of the enrollment, this is completion of the study.
Joon Lee: Got it. That’s really helpful. And similarly, with Alzheimer’s agitation, we can also expect top line data first half of this year [ph] or is that just to check?
Mark Jacobson: Yes. And then – similarly, with the Alzheimer’s disease agitation – the guidance of trial completion also incorporates – data read out.
Joon Lee: Perfect. And based on your experience with digital-centric commercial strategy in partnership with Veeva, is this something that you may also consider down the road for migraine, narcolepsy or ADHD or even Alzheimer’s? Thank you.
Mark Jacobson: The rationale behind putting together the platform is, I think, we could leverage it for our entire pipeline. So, we’re very glad that we made that investment, and we’re looking forward to leveraging it for – really vast pipeline that we haven’t raised a product candidate.
Lori Englebert: Yes. Joon I can just add one piece of commentary there. We are leveraging it for Sunosi now as well, so it is across both products that we are leveraging.
Joon Lee: Thank you.
Operator: Thank you. Next question today is coming from Jason Gerberry from Bank of America. Your line is now live.
Jason Gerberry: Good morning, guys. Thanks for taking my question. Just wanted to come back to the sales force the announcement. So, I guess will these new reps just be covering physicians or providers that were not being called on prior? I’m just trying to get a sense of – and I think in the past, the digital strategy was sort of like I thought, meant to improve breadth and productivity of each prescriber, but there’s also maybe a rep that’s calling on that provider. So just kind of wondering like what’s changed in terms of how you’ll leverage kind of the digital component and where the new reps will specifically be adding value?
